129 related articles for article (PubMed ID: 24778426)
21. Mannitol Prescribing Practices With Cisplatin Before and After an Educational Newsletter Intervention.
Corbin M; Bossaer JB
Hosp Pharm; 2017 May; 52(5):353-356. PubMed ID: 28804151
[No Abstract] [Full Text] [Related]
22. [Experimental studies on the nephrotoxicity of cisplatin--amelioration of nephrotoxicity by continuous infusion].
Izumi T
Hinyokika Kiyo; 1988 Jan; 34(1):37-45. PubMed ID: 3132030
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-induced nephrotoxicity in children: what is the best protective strategy?
Ruggiero A; Ariano A; Triarico S; Capozza MA; Romano A; Maurizi P; Mastrangelo S; Attinà G
J Oncol Pharm Pract; 2021 Jan; 27(1):180-186. PubMed ID: 32990190
[TBL] [Abstract][Full Text] [Related]
24. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.
Muraki K; Koyama R; Honma Y; Yagishita S; Shukuya T; Ohashi R; Takahashi F; Kido K; Iwakami S; Sasaki S; Iwase A; Takahashi K
J Thorac Dis; 2012 Dec; 4(6):562-8. PubMed ID: 23205279
[TBL] [Abstract][Full Text] [Related]
25. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Al-Sarraf M; Fletcher W; Oishi N; Pugh R; Hewlett JS; Balducci L; McCracken J; Padilla F
Cancer Treat Rep; 1982 Jan; 66(1):31-5. PubMed ID: 6796269
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin-induced nephrotoxicity in an outpatient setting.
Burns CV; Edwin SB; Szpunar S; Forman J
Pharmacotherapy; 2021 Feb; 41(2):184-190. PubMed ID: 33417725
[TBL] [Abstract][Full Text] [Related]
27. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
28. Response to "Nephrotoxicity: Evidence in Patients Receiving Cisplatin Therapy".
Nematbakhsh M
Clin J Oncol Nurs; 2018 Oct; 22(5):477-478. PubMed ID: 30239517
[TBL] [Abstract][Full Text] [Related]
29. Urine ratio of neutrophil gelatinase-associated lipocalin to creatinine as a marker for early detection of cisplatin-associated nephrotoxicity.
Shahbazi F; Sadighi S; Dashti-Khavidaki S; Shahi F; Mirzania M
Iran J Kidney Dis; 2015 Jul; 9(4):306-10. PubMed ID: 26174458
[TBL] [Abstract][Full Text] [Related]
30. [Clinical multivariate statistical analysis of nephrotoxicity induced by cisplatin].
Ding DC
Zhonghua Zhong Liu Za Zhi; 1992 Jan; 14(1):64-6. PubMed ID: 1396050
[TBL] [Abstract][Full Text] [Related]
31. Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage.
Kim MY; Park JH; Kang NR; Jang HR; Lee JE; Huh W; Kim YG; Kim DJ; Hong SC; Kim JS; Oh HY
J Neurosurg; 2014 Jun; 120(6):1340-8. PubMed ID: 24484224
[TBL] [Abstract][Full Text] [Related]
32. Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.
Sikking C; Niggebrugge-Mentink KL; van der Sman ASE; Smit RHP; Bouman-Wammes EW; Beex-Oosterhuis MM; van Kesteren C
Oncologist; 2024 Feb; 29(2):e173-e186. PubMed ID: 37995306
[TBL] [Abstract][Full Text] [Related]
33. Methods of reduction of cisplatin nephrotoxicity.
Walker EM; Gale GR
Ann Clin Lab Sci; 1981; 11(5):397-410. PubMed ID: 6277229
[TBL] [Abstract][Full Text] [Related]
34. Renal function of cancer patients "fit" for Cisplatin chemotherapy: physician perspective.
Montoya J; Luna HG; Amparo JR; Casasola C; Cristal-Luna G
Gulf J Oncolog; 2014 Jul; 1(16):64-72. PubMed ID: 25316394
[TBL] [Abstract][Full Text] [Related]
35. Hydration with Mannitol and Dextrose May Promote Cisplatin-Induced Nephrotoxicity: Test of Five Protocols of Hydration during Cisplatin Therapy in Rat Models.
Khosravi MS; Samimiat A; Mazaheri B; Ashrafi F; Talebi A; Nematbakhsh M
J Toxicol; 2021; 2021():5547341. PubMed ID: 34646321
[TBL] [Abstract][Full Text] [Related]
36. Renal and electrolyte disturbances associated with cisplatin.
Blachley JD; Hill JB
Ann Intern Med; 1981 Nov; 95(5):628-32. PubMed ID: 7027859
[TBL] [Abstract][Full Text] [Related]
37. Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity.
Polycarpe E; Arnould L; Schmitt E; Duvillard L; Ferrant E; Isambert N; Duvillard C; Beltramo JL; Chevet D; Chauffert B
Int J Cancer; 2004 Aug; 111(1):131-7. PubMed ID: 15185354
[TBL] [Abstract][Full Text] [Related]
38. [Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].
Ohhara Y; Isobe H; Ito K; Fuke S; Kojima T; Saito H; Nishiura Y
Gan To Kagaku Ryoho; 2015 Jan; 42(1):57-61. PubMed ID: 25596680
[TBL] [Abstract][Full Text] [Related]
39. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
[TBL] [Abstract][Full Text] [Related]
40. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
